A new drug in treatment of recurrent vulvovaginal candidiasis:oteseconazole
Recurrent vulvovaginal candidiasis(RVVC)is one of the common recurrent and refractory diseases that troubles women.Oteseconazole,the first drug for the treatment of RVVC,is an oral azole metallic enzyme inhibitor targeting fungal sterol 14 α-demethylase(CYP51)developed by Mycovia Pharmaceuticals,Inc.,and was approved for sale in the United States on April 26,2022.Clinical trials have shown that oteseconazole has a significant therapeutic effect on RVVC with minimal adverse reactions.
oteseconazolevulvovaginal candidiasisclinical study
NETL
NSTL
万方数据
